Ratio Therapeutics

#Hiring - Join Ratio Therapeutics!   We're on a mission to improve and extend the lives of #cancer patients without compromising their quality of life. We're seeking top talent to join our team of experts developing novel #radiotherapeutics.   ✔️ Dynamic, fast-paced environment ✔️ Global collaboration with researchers ✔️ World-class scientists and professionals   If you're passionate about groundbreaking cancer treatment research and want to make a real impact, we want to hear from you. Let's change the way cancer is treated together!   Visit our website to see open positions: https://lnkd.in/eQdxdGKw

Ratio was recently featured in this C&EN article from Aayushi Pratap about the growing field of #oncology #radiopharmaceuticals. Targeted radiopharmaceuticals are generally composed of a radioactive isotope, a chelating agent, a linker, and a target-binding domain. This article explores the options and considerations for choosing the right isotope. Full article: https://lnkd.in/eSJPySNa

Reminder! Tomorrow, Ratio’s CEO Jack Hoppin will be an expert speaker at the 3rd Annual Targeted Radiopharmaceuticals Summit, taking place July 30 – August 1, 2024 in San Diego, CA. He will be speaking at the following workshops on Tuesday, July 30: ⏱️ 8:30 am: Workshop A | Evaluating Novel Radiopharmaceutical Targeting Agents for Enhanced Specificity & Efficacy ⏱️ 11 am: Workshop E | Advancing Dosimetry Data: An Invaluable Tool to Optimize Therapeutic Outcomes For more details and to register, visit: https://lnkd.in/eXjc43na #radiopharmaceuticals #TRP #TRP24

Ratio’s CEO Jack Hoppin will be an expert speaker at the 3rd Annual Targeted Radiopharmaceuticals Summit, taking place July 30 – August 1, 2024 in San Diego, CA. He will be speaking at the following workshops on Tuesday, July 30: ⏱️ 8:30 am: Workshop A | Evaluating Novel Radiopharmaceutical Targeting Agents for Enhanced Specificity & Efficacy ⏱️ 11 am: Workshop E | Advancing Dosimetry Data: An Invaluable Tool to Optimize Therapeutic Outcomes For more details and to register, visit: https://lnkd.in/eXjc43na #radiopharmaceuticals #TRP #TRP24

The dynamic landscape of diagnostic and therapeutic radiopharmaceuticals, also known as theranostics, has expanded greatly over the past decade. The Lancet has recently published a series dedicated to this field, covering topics from the latest advances in radiochemistry to the building of global and equitable access to theranostic radiopharmaceuticals. https://lnkd.in/e6XHXa3D #radiopharmaceuticals #theranostics

Ratio’s CEO Jack Hoppin will be an expert speaker at the 3rd Annual Targeted Radiopharmaceuticals Summit, taking place July 30 – August 1, 2024 in San Diego, CA. He will be speaking at the following workshops on Tuesday, July 30: ⏱️ 8:30 am: Workshop A | Evaluating Novel Radiopharmaceutical Targeting Agents for Enhanced Specificity & Efficacy ⏱️ 11 am: Workshop E | Advancing Dosimetry Data: An Invaluable Tool to Optimize Therapeutic Outcomes For more details and to register, visit: https://lnkd.in/eXjc43na #radiopharmaceuticals #TRP #TRP24

Only a few days left! Ratio’s PanCAN PurpleStride 2024 fundraiser closes on June 30. Join us in supporting the fight against #pancreaticcancer. PanCAN PurpleStride is the primary way PanCAN raises money to fund vital research that can bring new treatment options to patients as well as providing free, personalized one-to-one support through PanCAN Patient Services. Donate here: https://lnkd.in/e-Pdap4h #fundraising #PanCANPurpleStride

#ICYMI - Thank you Vibha Ravi for speaking with Ratio co-founders Drs. Jack Hoppin and John Babich on the Citeline podcast. Listen to the full episode to hear about our recent Series B financing round, industry trends and the use of artificial intelligence in radiopharma. Learn more: https://lnkd.in/eyBFTzYi #biopharma #radiopharmaceuticals

Team Ratio had a wonderful time at #SNMMI24, with three team member presentations and many valuable insights gained from our colleagues in #cancer research and nuclear medicine! Thank you to the organizers at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) for putting on another great event. #research #data #radiopharmaceuticals

Today Ratio announced the appointment of Former U.S. Senator William "Mo" Cowan to its Board of Directors. Senator Cowan brings a wealth of experience in government, law, healthcare, and public policy to Ratio's Board. "I am excited to join the Ratio Therapeutics Board of Directors during a time when the radiopharmaceutical field has gained significant traction," said Senator Cowan, Ratio Board Member. "The recent discoveries and growth of the team at Ratio is encouraging. I look forward to combining my knowledge and skills with such talented individuals and helping support Ratio's goal to develop novel radiopharmaceuticals for the patients who need them the most." Read the full release here: https://lnkd.in/gke7BjHX #radiopharmaceuticals #radiotherapeutics #cancertherapy